Stoke Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: STOK · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing
Related Tickers: STOK
TL;DR
Stoke Therapeutics (STOK) filed an 8-K for a shareholder vote on June 5th.
AI Summary
Stoke Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 5, 2024. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates a formal process where security holders are being asked to vote on specific company matters, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — This is a routine corporate filing related to a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of earliest event reported
- June 6, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 45 Wiggins Ave (address) — Principal Executive Offices
- Bedford, Massachusetts (location) — Principal Executive Offices Location
- 01730 (zip_code) — Principal Executive Offices Zip Code
- (781) 430-8200 (phone_number) — Registrant's Telephone Number
FAQ
What specific matters were submitted for a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt of the 8-K.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 5, 2024.
What is the principal executive office address of Stoke Therapeutics, Inc.?
The principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts 01730.
What is the company's IRS Employer Identification No.?
The IRS Employer Identification No. is 47-1144582.
What is the SIC code for Stoke Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-06 16:06:30
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo
Filing Documents
- d795894d8k.htm (8-K) — 27KB
- 0001193125-24-156049.txt ( ) — 146KB
- stok-20240605.xsd (EX-101.SCH) — 3KB
- stok-20240605_lab.xml (EX-101.LAB) — 18KB
- stok-20240605_pre.xml (EX-101.PRE) — 11KB
- d795894d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Stoke Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38938 47-1144582 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 45 Wiggins Ave Bedford , Massachusetts 01730 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: (781) 430-8200 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.07 Submission of Matters to a Vote of Security Holders. On June 5, 2024, Stoke Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders, and the following proposals were adopted: 1. Election of three Class II directors, Jennifer C. Burstein, Arthur A. Levin, Ph.D. and Ian F. Smith, each to serve a three-year term, which will expire upon the earlier of the 2027 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified: Nominees Shares For Shares Withheld Broker Non-Votes Jennifer C. Burstein 32,396,633 1,970,217 5,561,508 Arthur A. Levin, Ph.D. 25,556,568 8,810,282 5,561,508 Ian F. Smith 33,961,032 405,818 5,561,508 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: Shares For Shares Against Shares Withheld/Abstaining 39,911,634 6,826 9,898 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 6, 2024 STOKE THERAPEUTICS, INC. By: /s/ Thomas Leggett Thomas Leggett Chief Financial Officer